-+ 0.00%
-+ 0.00%
-+ 0.00%

What Ipsen Shareholders Got Right

Simply Wall St·11/16/2026 01:20:46
Listen to the news

Kidney transplant doctors had a new name on their radar when Ipsen moved to buy Memo Therapeutics for more than €700 million, anchored on potravitug for BK polyomavirus nephropathy. Investors who held Ipsen from the start of the year are up 44.8%, including dividends. If you were deciding back on 1 January whether to own it, what did you have to believe about rare disease deals and future trial execution before any of this news arrived?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

The easy part of this move is behind Ipsen. Zero in on 197 high quality undervalued stocks for companies trading below our estimates.

The Two Ipsen Stories Investors Had To Weigh

The shares cost €119 at the start of the period, and Ipsen sat between two very different but credible scripts about where the business could head next.

On the bullish side, Ipsen was tied to a Fair Value of €128, or 8% above the start price. This was built on assumptions of 4.7% revenue growth, an 18.6% profit margin and a future P/E of 15.6x over three years, with wider access for drugs like Iqirvo and Bylvay seen as key.

The bearish narrative pinned Fair Value at €105, or 12% below the start price. It focused on tightening US and EU pricing controls plus heavier regulation that could keep revenue growth closer to 2.6% with profit margins nearer 13.8% and a future P/E of 18.1x.

ENXTPA:IPN Trailing 12-Month Earnings & Revenue History as at Nov 2026
ENXTPA:IPN Trailing 12-Month Earnings & Revenue History as at Nov 2026

What The Evidence Actually Tested For Ipsen

The clearest new fact was Ipsen’s rare disease and oncology deal flow, with completed acquisitions of Memo Therapeutics and Kartos plus advancing data for IQIRVO and Dysport. That supported the bullish story about pipeline depth and specialty focus. Reported H1 2026 figures also showed revenue and net income above H1 2025, with net margin at 17.5%. Overall, the evidence leaned toward the optimistic case but did not settle it.

The lesson is straightforward. When a thesis rests on deals and trial execution, treat each acquisition closing, clinical readout and next trial phase as checkpoints, and compare those events with the revenue and margin path management reports over time.

What Ipsen's Current Price Already Assumes

Ipsen’s shares now trade at €166 from the start of the year, so anyone buying today is paying well above where the cautious Narrative’s Fair Value sits below the current price.

That bearish analyst Narrative on Simply Wall St argues the business already carries a premium for strong margins and deal making. A buyer now is effectively betting Ipsen can keep reinvesting into oncology, rare disease and neuroscience without future earnings falling short of what this price bakes in.

"Although Ipsen highlights a growing rare liver disease franchise around Iqirvo and Bylvay, the BOLD Phase III failure in biliary atresia removes a planned label expansion that could have supported higher pricing power and volume, which may cap future Rare Disease revenue and narrow room for earnings upside versus expectations."

The price and this Narrative do not agree. → Uncover what this Narrative says Ipsen is actually worth

Where Ipsen’s Playbook Connects Out

Ipsen’s deal making and trial milestones highlight one theme for investors. Large pipelines rely on steady new products replacing aging franchises.

Another big drug maker confronts the same issue from a different angle. It leans on new obesity agents and antibody drug conjugates to refresh its mix.

The aim is similar to Ipsen’s focus in rare disease and oncology. Both pursue therapies that can support broader portfolios over time.

What you track with Ipsen, you can mirror there. Pipeline execution, cost discipline and shifting product weight shape how that story develops.

That argument has a Narrative and a number behind it. → See the company one Narrative values 28% above its price